Swiss National Bank Purchases 12,700 Shares of Apogee Therapeutics Inc. $APGE

Swiss National Bank increased its position in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 20.2% during the first quarter, HoldingsChannel reports. The fund owned 75,600 shares of the company’s stock after buying an additional 12,700 shares during the quarter. Swiss National Bank’s holdings in Apogee Therapeutics were worth $6,363,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC raised its position in Apogee Therapeutics by 2.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock valued at $540,000 after purchasing an additional 152 shares during the last quarter. Stifel Financial Corp grew its holdings in shares of Apogee Therapeutics by 3.5% during the fourth quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock worth $394,000 after purchasing an additional 175 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Apogee Therapeutics during the fourth quarter worth about $25,000. Comerica Bank increased its stake in shares of Apogee Therapeutics by 1.0% in the fourth quarter. Comerica Bank now owns 35,872 shares of the company’s stock valued at $2,708,000 after buying an additional 338 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Apogee Therapeutics in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the sale, the insider directly owned 179,248 shares of the company’s stock, valued at approximately $23,768,284.80. The trade was a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $132.54, for a total transaction of $10,603,200.00. Following the transaction, the chief executive officer owned 1,015,987 shares in the company, valued at $134,658,916.98. This represents a 7.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 182,900 shares of company stock worth $21,711,585. 24.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on APGE. The Goldman Sachs Group set a $89.00 price objective on shares of Apogee Therapeutics in a report on Thursday, May 28th. Royal Bank Of Canada upped their price target on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the company a “sector perform” rating in a research report on Monday, June 8th. Mizuho restated a “neutral” rating and issued a $135.00 price target (up from $110.00) on shares of Apogee Therapeutics in a research report on Wednesday, June 24th. UBS Group downgraded shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and raised their price target for the company from $100.00 to $135.11 in a research note on Tuesday, June 23rd. Finally, Wedbush lowered shares of Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price target on the stock. in a report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $121.25.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $134.17 on Wednesday. The stock has a market capitalization of $8.30 billion, a price-to-earnings ratio of -30.99 and a beta of 0.32. Apogee Therapeutics Inc. has a 52-week low of $34.34 and a 52-week high of $134.46. The stock’s 50 day moving average price is $110.79 and its two-hundred day moving average price is $88.88.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, May 11th. The company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.01. On average, equities research analysts forecast that Apogee Therapeutics Inc. will post -4.45 EPS for the current year.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor ROR?t, a master regulator of T cell-driven inflammatory pathways. By modulating ROR?t activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral ROR?t inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.